Patent · US Active

Crystalline salts of a B-RAF kinase inhibitor

US11753409B2 · kind B2 · utility

0Cited by

2References

16Claims

0Family size

Assignee

Xynomic Pharmaceuticals, Inc. · US

Inventors

Ulrike Werthmann · Biberach an der Riß, DE
Gerd-Michael Maier · Ingelheim am Rhein, DE
Bodo Betzemeier · Biberach an der Riß, DE
Otmar Schaaf · Wien, AT

Key dates

Filing date	Mar 11, 2022
Grant date	Sep 12, 2023
Priority date	—
Expiry date	May 19, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The present invention is related to crystalline salts of N-(3-(5-((1-ethylpiperidin-4-yl)(methyl)amino)-3-(pyrimidin-5-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-2,4-difluorophenyl)propane-1-sulfonamide, a RAF kinase Inhibitor, useful in the treatment of cancer and other diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.